Skip to content
PoliticalRepoPoliticalRepo

United States · Bill · HR

H.R. 2999 (115th)

Patients' Access to Treatments Act of 2017

referredUnited States· United States Congress· EN

Introduced

22 June 2017

Last action

23 June 2017 · Referred

Status

Referred to the Subcommittee on Health.

Sponsors

Rep. McKinley, David B. [R-WV-1], Rep. Butterfield, G. K. [D-NC-1], Rep. Cicilline, David N. [D-RI-1], Rep. Smith, Christopher H. [R-NJ-4], Rep. Ryan, Tim [D-OH-13], Rep. Takano, Mark [D-CA-39], Rep. Langevin, James R. [D-RI-2], Rep. Connolly, Gerald E. [D-VA-11], Rep. Napolitano, Grace F. [D-CA-32], Rep. Slaughter, Louise McIntosh [D-NY-25], Rep. Bonamici, Suzanne [D-OR-1], Rep. Pingree, Chellie [D-ME-1], Rep. Maloney, Carolyn B. [D-NY-12], Rep. Clark, Katherine M. [D-MA-5], Rep. McGovern, James P. [D-MA-2], Rep. Ellison, Keith [D-MN-5], Sen. Schiff, Adam B. [D-CA], Rep. Aguilar, Pete [D-CA-33], Rep. Pocan, Mark [D-WI-2], Rep. Eshoo, Anna G. [D-CA-18], Rep. DeFazio, Peter A. [D-OR-4], Rep. King, Peter T. [R-NY-2], Rep. Barletta, Lou [R-PA-11], Rep. Palazzo, Steven M. [R-MS-4], Rep. Rice, Kathleen M. [D-NY-4], Rep. Raskin, Jamie [D-MD-8], Rep. Loebsack, David [D-IA-2], Rep. Comstock, Barbara [R-VA-10], Rep. Sensenbrenner, F. James, Jr. [R-WI-5], Rep. Frelinghuysen, Rodney P. [R-NJ-11], Rep. Kildee, Daniel T. [D-MI-5], Rep. Speier, Jackie [D-CA-14], Rep. O'Halleran, Tom [D-AZ-1], Rep. Wittman, Robert J. [R-VA-1], Rep. Blumenauer, Earl [D-OR-3], Rep. Cohen, Steve [D-TN-9]

Subjects

Healthcare

Source updated

11 August 2025

Healthcare

Official sourceDownload fileView documentsShare

Summary

Patients' Access to Treatments Act of 2017 This bill amends the Public Health Service Act to establish cost sharing limits for health plans that cover prescription drugs and use a formulary or other tiered cost sharing structure. Such health plans may not impose higher cost sharing requirements, including copayment and coinsurance, for specialty drugs than for other prescription drugs in a nonpreferred brand name drug tier. If a health plan's formulary contains more than one nonpreferred brand name drug tier, the tier with the lowest cost sharing applies.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 22 June 2017

    Introduced

    Referred to the House Committee on Energy and Commerce.

    Source: IntroReferral

  2. 22 June 2017

    Introduced

    Introduced in House

    Source: IntroReferral

  3. 22 June 2017

    Introduced

    Introduced in House

    Source: IntroReferral

  4. 23 June 2017

    Referred

    Referred to the Subcommittee on Health.

    Source: Committee

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Introduced in House (text)

View fileDownload file

This file cannot be previewed here. Use View or Download.

Leesvertaling

Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House (text)

    Introduced in House · EN · 22 June 2017

    ViewDownloadOpen at official source

  • Introduced in House (PDF)

    Introduced in House · EN · 22 June 2017

    ViewDownloadOpen at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

  • Introduced in House

    summary · EN · 22 June 2017

    Open at official source

    Leesvertaling

    Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.

    Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.

Sponsors

Related records

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.